A practical reference on HPLC-UV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-19. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
When cannabis is cultivated for its psychoactive or medicinal properties, male plants will often be separated from females. This prevents fertilization of the female plants, either to facilitate sin semilla flowering or to provide more control over which male is chosen. Pollen produced by the male is caught and stored until it is needed. When a male plant of one strain pollinates a female of another strain, the seeds will be F1 hybrids of the male and female. These offspring will not be identical to their parents. Instead, they will have characteristics of both parents. Repeated breeding results in certain characteristics appearing with greater regularity. It is impossible for a hermaphrodite to create any male-only seeds. A hermaphrodite may create female only seeds and hermaphrodite seeds. Also the female-only seeds may carry the hermaphrodite trait. Hybridization is the process of plants and animals breeding. Natural wind currents help speed up this hybridization process and promotes a positive growth. Some plants produce many seeds while some produce little to none depending on how it is bred. If seeds are produced traits from both the original parents will be expressed. Techniques such as mutation breeding are used to develop new strains using irradiation or chemical mutagens such as colchicine. Various companies have been experimenting with creating new strains using genetic engineering techniques.
== In popular culture == King Naram-Sin is a character in the 2021 video game House of Ashes, with the main plot occurring in his personal temple. In the game, he is the self-proclaimed "God King" of Akkad, and is engaged in a war with the Gutians after being cursed by the god Enlil; whom he angered after the sacking of his temple. Naram-Sin was voiced and motion captured by Sami Karim. In the 2021 mobile gacha game Blue Archive, Volume F, the innermost chamber of the large floating quantum supercomputer known as the "Ark of Atra-Hasis" (itself a reference to the Akkadian myth) is named "Throne of Naram-Sin".
Aquileia virtual tour (Italian Landmarks) Pre-Roman and Celtic Aquileia Explore the Archaeological Area and the Patriarchal Basilica of Aquileia in the UNESCO collection on Google Arts and Culture Aquileia featured on 10 Euro Italian Coin
Pocket watches are uncommon in the present day, having first been superseded by wristwatches and later by smartphones. Until early in the 20th century, though, the pocket watch remained predominant for men, with the wristwatch considered feminine and unmanly. In men's fashions, pocket watches began to be superseded by wristwatches around the time of World War I, when officers in the field began to appreciate that a watch worn on the wrist was more easily accessed than one kept in a pocket. A watch of transitional design, combining features of pocket watches and modern wristwatches, was called a "trench watch" or "wristlet". The more accurate pocket watches continued to be widely used in railroading even as their popularity declined elsewhere. Quartz pocket watches are available in the present day, retaining the form and function of the original pocket watches while using a quartz crystal as opposed to the traditional fully-mechanical movement. For a few years in the late 1970s and early 1980s three-piece suits for men returned to fashion, and this led to small resurgence in pocket watches, as some men actually used the vest pocket for its original purpose. Since then, some watch companies continue to make pocket watches. As vests have long since fallen out of fashion (in the US) as part of formal business wear, the only available location for carrying a watch is in a trouser pocket.
Sources: en.wikipedia.org
Lurasidone, sold under the brand name Latuda among others, is an atypical antipsychotic medication used to treat schizophrenia and bipolar depression. It is taken by mouth. Common side effects include sedation, indigestion, nausea, and insomnia. At higher dosages, there is an increased risk for restlessness and movement problems. Serious side effects are valid for all atypical antipsychotics and may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, angioedema, and high blood sugar levels. Although lurasidone is less likely to cause high blood sugar levels in most patients, hyperosmolar hyperglycemic syndrome may occur. In older people with psychosis as a result of dementia, it may increase the risk of dying. Use during pregnancy is of unclear safety. Lurasidone was first approved for medical use in the United States in 2010, for treating schizophrenia. In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as monotherapy or adjunctively with lithium or valproate. It is not FDA approved for treating manic symptoms associated with bipolar disorder despite its FDA approval for treating bipolar depression. Generic versions were approved in the United States in 2019, and became available in 2023. In 2021, it was the 193rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.
=== 28 May === The Mayor of Kyiv, Vitali Klitschko, claimed that Russian drones attacked the Ukrainian capital. Two people were killed by falling drone debris, while a woman was injured. Two high-rise apartments were set on fire. The Ukrainian Air Force claimed that 58 out of 59 drones had been shot down, with more than 40 of them intercepted over Kyiv. Fires were reported in the Solomyanskyi, Holosiivskyi and Pecherskyi Districts. The attack came on the anniversary of Kyiv's founding in 482 AD. It was later described as Russia's largest drone attack on Kyiv since the war began. Air raid alerts were activated in 12 oblasts, from Volyn in the north-west to Dnipropetrovsk in the south-east. There were also reports of explosions in Zhytomyr, where at least 26 residential buildings were damaged as well as schools and medical units. Shelling was also reported in Sumy Oblast, which borders Russia, and in Nikopol, across the Dnipro River from the Zaporizhzhia Nuclear Power Plant. Russia said its air defences shot down several drones approaching the Ilsky oil refinery in Krasnodar Krai. The Ukrainian General Staff claimed that 80 Russian soldiers deserted their positions in Lysychansk, Luhansk Oblast, while 30 others deserted from Bakhmut. Valerii Zaluzhnyi, Commander-in-Chief of the Armed Forces of Ukraine, reported that all the preparations for the anticipated major counter-attack are complete and that they were only waiting for the decision to strike.
== See also == Angiogenesis Bone growth factor Cytokine Growth factor receptor Human Genome Organisation Mitogen Neurotrophic factor Receptor (biochemistry) Signal transduction Wound healing § Overview of involved growth factors
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.